EUCTR2012-005026-30-BG进行中（未招募）不适用
A Randomised, Double-Blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SB4 Compared to Enbrel® in Subjects with Moderate to Severe Rheumatoid Arthritis despite Methotrexate Therapy
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 596
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Are male or female aged 18–75 years at the time of signing the consent form.
- •2. Have been diagnosed as having RA according to the revised 1987 American College of Rheumatology (ACR) criteria
- •3. Have more than or equal to six swollen joints, more than or equal to six tender joints (from the 66/68 joint count system) at Screening and Randomisation and either erythrocyte sedimentation rate (Westergren) = 28 mm/h or serum C-reactive protein = 1.0 mg/dL at Screening.
- •4. Must have been treated with MTX for at least 6 months prior to Randomisation and on a stable dose of MTX 10–25 mg/week given orally or parenterally for at least 4 weeks prior to Screening.
- •5. Female subjects who are not pregnant or nursing at Screening and who are not planning to become pregnant from Screening until 2 months after the last dose of investigational product (IP).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 520
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 76
排除标准
- •1. Have been treated previously with any biological agents including any tumour necrosis factor inhibitor.
- •2. Have a known hypersensitivity to human immunoglobulin proteins or other components of Enbrel or SB4.
- •3. Have a positive serological test for hepatitis B or hepatitis C or have a known history of infection with human immunodeficiency virus.
- •4. Have a current diagnosis of active tuberculosis
- •5. Have had a serious infection or have been treated with intravenous antibiotics for an infection within 8 weeks or oral antibiotics within 2 weeks prior to Randomisation.
- •6. Have any of the following conditions
- •a. Other inflammatory or rheumatic diseases.
- •b. History of any malignancy within the previous 5 years prior to Screening
- •c. History of lymphoproliferative disease including lymphoma.
- •d. History of congestive heart failure
- •e. Physical incapacitation (ACR functional Class IV or wheelchair-/bed-bound).
- •f History of demyelinating disorders.
研究者
相似试验
进行中（未招募）
不适用
A Study Comparing SB4 to Enbrel® in Subjects with Moderate to Severe Rheumatoid Arthritis despite Methotrexate TherapySubjects with Moderate to Severe Rheumatoid Arthritis despite Methotrexate Therapy. The intended use of SB4 is Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), plaque Psoriasis (PsO) and paediatric plaque PsO.MedDRA version: 17.1Level: SOCClassification code 10021428Term: Immune system disordersSystem Organ Class: 10021428 - Immune system disordersEUCTR2012-005026-30-PLSamsung Bioepis Co., Ltd.596
进行中（未招募）
1 期
Clinical study on an antiallergic therapy, which will be administered against rhinitis and/or rhinoconjunctivitis as allergic reaction to grass pollen. The study drug Depigoid® Phleum used for this immunotherapy in 4 different concentrations is a chemically modified extract of grass pollen.Allergic rhinitis and/or allergic rhinoconjunctivitis with or without intermittent asthma.MedDRA version: 13.1Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisSystem Organ Class: 10015919 - Eye disordersMedDRA version: 13.1Level: LLTClassification code 10001723Term: Allergic rhinitisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 13.1Level: LLTClassification code 10001705Term: Allergic asthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-018562-23-CZETI Pharma GmbH320
进行中（未招募）
不适用
Blinded, randomly distributed 4-group study for finding the most efficient dose of Depigoid® Phleum in patients with hay fever with/without asthma.Allergic Rhinitis and/or Rhinoconjunctivitis with or without Intermittent AsthmaMedDRA version: 14.1Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: LLTClassification code 10001723Term: Allergic rhinitisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 14.1Level: LLTClassification code 10001705Term: Allergic asthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2012-000416-28-CZETI Pharma GmbH320
进行中（未招募）
1 期
A Randomised, Double-Blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SB4 Compared to Enbrel® in Subjects with Moderate to Severe Rheumatoid Arthritis despite Methotrexate TherapyEUCTR2012-005026-30-HUSamsung Bioepis Co., Ltd.596
进行中（未招募）
1 期
Blinded, randomly distributed 5-group study for finding the most efficient dose of Depigoid® Phleum versus placebo in patients with hay fever with or without asthmaAllergic Rhinitis and / or Rhinoconjunctivitis with or without Intermittent AsthmaMedDRA version: 19.0Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisSystem Organ Class: 100000004853MedDRA version: 19.0Level: LLTClassification code 10001705Term: Allergic asthmaSystem Organ Class: 100000004855MedDRA version: 19.0Level: LLTClassification code 10001723Term: Allergic rhinitisSystem Organ Class: 100000004855EUCTR2014-004732-19-PLETI Pharma GmbH200